OCC 2016:钱菊英——血管痉挛性心绞痛诊治及中国专家共识解读

2016-05-26 MedSci MedSci原创

第十届东方心脏病学会议(The  10th  Oriental Congress of Cardiology,OCC 2016)于今天开始在上海世博中心(浦东新区世博大道 1500 号) 召开。梅斯医学(MedSci)作为官方媒体受邀参加此次大会。   在今天早上的2016年上海市医学会心血管病分会年会上,第十届东方心脏病学会议大会秘书长、复旦大学附属中山医院心内

第十届东方心脏病学会议(The 10th Oriental Congress of Cardiology,OCC 2016)于今天开始在上海世博中心(浦东新区世博大道 1500 号) 召开。梅斯医学(MedSci)作为官方媒体受邀参加此次大会。

在今天早上的2016年上海市医学会心血管病分会年会上,第十届东方心脏病学会议大会秘书长、复旦大学附属中山医院心内科副主任医师、钱菊英教授做了题为《血管痉挛性心绞痛诊治及中国专家共识解读》的精彩演讲。

一、为什么制定中国共识?

1、发病率高


日本多中心研究显示,冠脉粥样硬化的胸痛患者中,乙酰胆碱试验阳性率43%。

2014年Circulation发表的临床基本特征相似的921例高加索人的阳性率为33.4%

2、并非良性疾病:

大部分患者对药物治疗(CCB、Nirtrates)效果良好,但5%~30%为药物难治性。

大部分患者预后良好,大部分可诱导AMI和恶性心律失常,心源性猝死率2%~16%。

3、了解不足


80年代前痉挛机制曾一度被认为是心绞痛的主要机制

80年代后血栓机制深入人心,而痉挛备受忽视

二、血管痉挛性心绞痛的概念演变

1、变异性心绞痛:静息性胸痛发作时检测到一过性ST段抬高

2、血管痉挛性心绞痛:ST段压低性心绞痛更多见;运动也可诱发;现在常用这个概念

3、冠状动脉痉挛综合征:冠脉痉挛广泛参与心脏病发生发展(不常用)

三、危险因素

1、主要危险因素:吸烟和血脂代谢紊乱(分别使CASS风险增加3.2倍和1.3倍)

2、其他诱因:可卡因、酗酒、介入、过敏、扩冠药物停用

3、非危险因素:如高血压、糖尿病



好发于40岁以上的人群,男性比女性多见

四、发病机制

1、血管内皮结构和功能紊乱:ET/NO比值升高

2、血管平滑肌反应性增高:Rho激酶途径

3、自主神经功能障碍:发作时迷走活性占优

4、遗传易感性:与NO合酶相关基因等

五、典型CAS性心绞痛(变异型心绞痛)的特点

1、有吸烟、血脂异常、可卡因、酗酒、高血压、糖尿病等危险因素

2、发作有昼夜节律(后半夜)至上午发作多见

3、运动耐量昼夜变化:清晨轻微劳力即可诱发,午后剧烈活动也不会诱发

4、典型者的心电图有一过性ST段抬高和T波高耸

5、冠状动脉造影多可见动脉硬化斑块;激发试验多诱发出局限性或节段性痉挛。



变异性心绞痛发作三大典型心电图:单独ST段抬高、ST段抬高伴快速性室性心律失常、ST段抬高伴房室传导阻滞。

六、冠脉痉挛的临床表现及诊断

冠脉痉挛的临床表现常具有复杂性

1、ST段下移更为常见冠脉痉挛时心电图ST段下移和(或)T波倒置较ST段抬高更为常见,病理基础为冠脉闭塞不完全或伴侧支形成,产生非透壁性心肌缺血。即非典型CAS性心绞痛。

2、无症状性缺血更为常见

CAS所引起的无症状性心肌缺血较常见,动态心电图监测可表现为ST段抬高或压低,而无明显症状。

3、可能以猝死或晕厥为首发症状

左冠状动脉痉挛多表现为室性心律失常,严重者可发生室性心动过速、室颤、甚至猝死。

右冠状动脉痉挛则多表现为心动过缓、窦性停搏或完全性房室传导阻滞。

若猝死前有大量吸烟、吸毒或大量饮酒病史,更应高度怀疑CAS诱发严重心律失常所致。

4、冠脉痉挛性AMI

闭塞性痉挛持续不能缓解即AMI;常有精神创伤、过度劳累、大量烟酒、吸毒史。

症状缓解或在冠脉硝甘后,造影显示无显著狭窄;长时痉挛可继发血栓,但抽烟后多无显著残余狭窄。

5、CAS诱发心力衰竭

严重的一过性缺血可导致暂时性室壁运动异常,诱发一过性心衰。冠脉痉挛反复发作可使心肌冬眠,降低心肌收缩力,诱发慢性左室功能障碍,抗痉挛治疗对这些心衰患者有效。



冠状动脉痉挛综合征诊断与治疗中国专家共识

冠脉痉挛诊断时,常规检查价值有限

1、心电图:虽然静息性胸痛合并一过性ST段抬高可直接临床诊断,但只有极少数患者能及时行心电图检查。而且,ST段压低更为多见,无法确诊。

2、动态心电图:并不一定能捕捉到CAS发作(上午检查的效果会较好)

3、运动平板试验:白天甚少发作,价值有限

4、冠脉造影:发现自发痉挛的概率极低

5、激发试验:

非创伤性激发试验因敏感性太低难以满足诊断要求。

创伤性药物激发试验(麦角新碱、乙酰胆碱):是目前诊断CASS的“金标准”,但存在安全隐患。

七、治疗

1、急性发作期治疗


急性发作时,舌下含服TG常可缓解胸痛

如不缓解,可静脉或冠脉使用硝酸酯类

如不缓解,加用口服或静脉短效快效CCB

冠脉痉挛急诊处理原则:


冠脉痉挛性室颤和心跳骤停:除颤基础上硝酸酯类扩冠治疗

冠脉痉挛性心源性休克:IABP基础上硝酸酯类扩冠治疗;肾上腺素和多巴胺可能加重痉挛

冠脉痉挛性心律失常:抗心律失常药作用甚微

明确室颤和心跳骤停是否与冠脉痉挛有关非常重要

临床上遇见伴有显著ST段改变、难治性室速室颤、三度AVB时,应考虑到冠脉痉挛的可能

2、稳定期治疗

(1)控制诱发因素:戒烟、戒酒、控制血压、维持适当的体重、纠正糖、脂代谢紊乱、避免过度劳累、勿随意停用扩冠药物等

(2)扩冠治疗

一线:CCB,抑制血管平滑肌Ca2+内流,解除痉挛,首选用药(几乎没有禁忌症)

二线:硝酸酯类,松弛血管平滑肌(存在耐药现象)

三线:选择性α阻滞剂哌唑嗪、KATP开放剂尼克地尔、Rho激酶抑制剂法舒地尔、静脉镁

(3)其他药物:他汀类、抗血小板药、β受体阻滞剂(对无冠脉狭窄的CASS患者禁忌单独使用)

(4)给药时间:晚上睡前服用

3、ICD治疗


共识指出:对于因CAS诱发的持续性实行心动过速或室颤等所导致的心脏骤停存活患者中,在规范药物治疗下仍反复发作者,可在进行充分评估的基础上考虑安装埋藏式自动除颤起搏器。

4、支架治疗


共识指出:
CASS患者原则上不主张介入治疗,个案报告显示,中重度冠状动脉狭窄基础上合并CAS可能从介入治疗中获益。

八、小结

1、VSA并不少见,常以“疑难病例”形象出现

2、并非良性疾病,治疗不当可猝死

3、戒烟是前提,CCB是基础

4、高危者可器械治疗,但证据不足

关于梅斯医学

梅斯医学(MedSci)是中国领先的医生互联网平台,拥有超过120万注册医生用户,主要从事临床研究、医生继续教育和培训,以及智慧医疗服务,旨在推动和加速临床医生的职业成长,改善医疗质量。
  扫描并识别上方二维码,即可下载梅斯医学APP,了解更多精彩!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=177406, encodeId=e8761e740656, content=我想问一下,抗血小板是选用单抗还是双抗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70111962588, createdName=1e13c6a4m70(暂无匿称), createdTime=Wed Feb 22 09:38:31 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844478, encodeId=5b5318444e805, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Aug 04 10:38:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971676, encodeId=981a19e1676af, content=<a href='/topic/show?id=0ce689e223e' target=_blank style='color:#2F92EE;'>#血管痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89722, encryptionId=0ce689e223e, topicName=血管痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Thu Nov 10 07:38:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741357, encodeId=a1081e41357d9, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 30 10:38:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086161, encodeId=f069208616154, content=<a href='/topic/show?id=cee996501dd' target=_blank style='color:#2F92EE;'>#钱菊英#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96501, encryptionId=cee996501dd, topicName=钱菊英)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Mon Jul 11 09:38:00 CST 2016, time=2016-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311740, encodeId=0a8d1311e4079, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353022, encodeId=71f213530227e, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87302, encodeId=4a1f8e302c8, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c81702726, createdName=Feng he, createdTime=Fri May 27 10:39:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87295, encodeId=86b38e295cc, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri May 27 06:59:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2017-02-22 1e13c6a4m70(暂无匿称)

    我想问一下,抗血小板是选用单抗还是双抗?

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=177406, encodeId=e8761e740656, content=我想问一下,抗血小板是选用单抗还是双抗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70111962588, createdName=1e13c6a4m70(暂无匿称), createdTime=Wed Feb 22 09:38:31 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844478, encodeId=5b5318444e805, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Aug 04 10:38:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971676, encodeId=981a19e1676af, content=<a href='/topic/show?id=0ce689e223e' target=_blank style='color:#2F92EE;'>#血管痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89722, encryptionId=0ce689e223e, topicName=血管痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Thu Nov 10 07:38:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741357, encodeId=a1081e41357d9, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 30 10:38:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086161, encodeId=f069208616154, content=<a href='/topic/show?id=cee996501dd' target=_blank style='color:#2F92EE;'>#钱菊英#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96501, encryptionId=cee996501dd, topicName=钱菊英)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Mon Jul 11 09:38:00 CST 2016, time=2016-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311740, encodeId=0a8d1311e4079, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353022, encodeId=71f213530227e, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87302, encodeId=4a1f8e302c8, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c81702726, createdName=Feng he, createdTime=Fri May 27 10:39:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87295, encodeId=86b38e295cc, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri May 27 06:59:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=177406, encodeId=e8761e740656, content=我想问一下,抗血小板是选用单抗还是双抗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70111962588, createdName=1e13c6a4m70(暂无匿称), createdTime=Wed Feb 22 09:38:31 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844478, encodeId=5b5318444e805, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Aug 04 10:38:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971676, encodeId=981a19e1676af, content=<a href='/topic/show?id=0ce689e223e' target=_blank style='color:#2F92EE;'>#血管痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89722, encryptionId=0ce689e223e, topicName=血管痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Thu Nov 10 07:38:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741357, encodeId=a1081e41357d9, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 30 10:38:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086161, encodeId=f069208616154, content=<a href='/topic/show?id=cee996501dd' target=_blank style='color:#2F92EE;'>#钱菊英#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96501, encryptionId=cee996501dd, topicName=钱菊英)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Mon Jul 11 09:38:00 CST 2016, time=2016-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311740, encodeId=0a8d1311e4079, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353022, encodeId=71f213530227e, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87302, encodeId=4a1f8e302c8, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c81702726, createdName=Feng he, createdTime=Fri May 27 10:39:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87295, encodeId=86b38e295cc, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri May 27 06:59:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=177406, encodeId=e8761e740656, content=我想问一下,抗血小板是选用单抗还是双抗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70111962588, createdName=1e13c6a4m70(暂无匿称), createdTime=Wed Feb 22 09:38:31 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844478, encodeId=5b5318444e805, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Aug 04 10:38:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971676, encodeId=981a19e1676af, content=<a href='/topic/show?id=0ce689e223e' target=_blank style='color:#2F92EE;'>#血管痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89722, encryptionId=0ce689e223e, topicName=血管痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Thu Nov 10 07:38:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741357, encodeId=a1081e41357d9, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 30 10:38:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086161, encodeId=f069208616154, content=<a href='/topic/show?id=cee996501dd' target=_blank style='color:#2F92EE;'>#钱菊英#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96501, encryptionId=cee996501dd, topicName=钱菊英)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Mon Jul 11 09:38:00 CST 2016, time=2016-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311740, encodeId=0a8d1311e4079, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353022, encodeId=71f213530227e, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87302, encodeId=4a1f8e302c8, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c81702726, createdName=Feng he, createdTime=Fri May 27 10:39:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87295, encodeId=86b38e295cc, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri May 27 06:59:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=177406, encodeId=e8761e740656, content=我想问一下,抗血小板是选用单抗还是双抗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70111962588, createdName=1e13c6a4m70(暂无匿称), createdTime=Wed Feb 22 09:38:31 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844478, encodeId=5b5318444e805, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Aug 04 10:38:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971676, encodeId=981a19e1676af, content=<a href='/topic/show?id=0ce689e223e' target=_blank style='color:#2F92EE;'>#血管痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89722, encryptionId=0ce689e223e, topicName=血管痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Thu Nov 10 07:38:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741357, encodeId=a1081e41357d9, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 30 10:38:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086161, encodeId=f069208616154, content=<a href='/topic/show?id=cee996501dd' target=_blank style='color:#2F92EE;'>#钱菊英#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96501, encryptionId=cee996501dd, topicName=钱菊英)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Mon Jul 11 09:38:00 CST 2016, time=2016-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311740, encodeId=0a8d1311e4079, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353022, encodeId=71f213530227e, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87302, encodeId=4a1f8e302c8, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c81702726, createdName=Feng he, createdTime=Fri May 27 10:39:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87295, encodeId=86b38e295cc, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri May 27 06:59:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-07-11 bnjfy
  6. [GetPortalCommentsPageByObjectIdResponse(id=177406, encodeId=e8761e740656, content=我想问一下,抗血小板是选用单抗还是双抗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70111962588, createdName=1e13c6a4m70(暂无匿称), createdTime=Wed Feb 22 09:38:31 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844478, encodeId=5b5318444e805, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Aug 04 10:38:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971676, encodeId=981a19e1676af, content=<a href='/topic/show?id=0ce689e223e' target=_blank style='color:#2F92EE;'>#血管痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89722, encryptionId=0ce689e223e, topicName=血管痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Thu Nov 10 07:38:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741357, encodeId=a1081e41357d9, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 30 10:38:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086161, encodeId=f069208616154, content=<a href='/topic/show?id=cee996501dd' target=_blank style='color:#2F92EE;'>#钱菊英#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96501, encryptionId=cee996501dd, topicName=钱菊英)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Mon Jul 11 09:38:00 CST 2016, time=2016-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311740, encodeId=0a8d1311e4079, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353022, encodeId=71f213530227e, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87302, encodeId=4a1f8e302c8, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c81702726, createdName=Feng he, createdTime=Fri May 27 10:39:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87295, encodeId=86b38e295cc, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri May 27 06:59:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-05-28 apoenzyme
  7. [GetPortalCommentsPageByObjectIdResponse(id=177406, encodeId=e8761e740656, content=我想问一下,抗血小板是选用单抗还是双抗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70111962588, createdName=1e13c6a4m70(暂无匿称), createdTime=Wed Feb 22 09:38:31 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844478, encodeId=5b5318444e805, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Aug 04 10:38:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971676, encodeId=981a19e1676af, content=<a href='/topic/show?id=0ce689e223e' target=_blank style='color:#2F92EE;'>#血管痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89722, encryptionId=0ce689e223e, topicName=血管痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Thu Nov 10 07:38:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741357, encodeId=a1081e41357d9, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 30 10:38:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086161, encodeId=f069208616154, content=<a href='/topic/show?id=cee996501dd' target=_blank style='color:#2F92EE;'>#钱菊英#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96501, encryptionId=cee996501dd, topicName=钱菊英)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Mon Jul 11 09:38:00 CST 2016, time=2016-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311740, encodeId=0a8d1311e4079, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353022, encodeId=71f213530227e, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87302, encodeId=4a1f8e302c8, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c81702726, createdName=Feng he, createdTime=Fri May 27 10:39:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87295, encodeId=86b38e295cc, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri May 27 06:59:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-05-28 zhaojie88
  8. [GetPortalCommentsPageByObjectIdResponse(id=177406, encodeId=e8761e740656, content=我想问一下,抗血小板是选用单抗还是双抗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70111962588, createdName=1e13c6a4m70(暂无匿称), createdTime=Wed Feb 22 09:38:31 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844478, encodeId=5b5318444e805, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Aug 04 10:38:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971676, encodeId=981a19e1676af, content=<a href='/topic/show?id=0ce689e223e' target=_blank style='color:#2F92EE;'>#血管痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89722, encryptionId=0ce689e223e, topicName=血管痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Thu Nov 10 07:38:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741357, encodeId=a1081e41357d9, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 30 10:38:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086161, encodeId=f069208616154, content=<a href='/topic/show?id=cee996501dd' target=_blank style='color:#2F92EE;'>#钱菊英#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96501, encryptionId=cee996501dd, topicName=钱菊英)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Mon Jul 11 09:38:00 CST 2016, time=2016-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311740, encodeId=0a8d1311e4079, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353022, encodeId=71f213530227e, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87302, encodeId=4a1f8e302c8, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c81702726, createdName=Feng he, createdTime=Fri May 27 10:39:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87295, encodeId=86b38e295cc, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri May 27 06:59:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-05-27 Feng he

    第一次看到,很有意思

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=177406, encodeId=e8761e740656, content=我想问一下,抗血小板是选用单抗还是双抗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70111962588, createdName=1e13c6a4m70(暂无匿称), createdTime=Wed Feb 22 09:38:31 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844478, encodeId=5b5318444e805, content=<a href='/topic/show?id=5d2f206482e' target=_blank style='color:#2F92EE;'>#专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20648, encryptionId=5d2f206482e, topicName=专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Thu Aug 04 10:38:00 CST 2016, time=2016-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1971676, encodeId=981a19e1676af, content=<a href='/topic/show?id=0ce689e223e' target=_blank style='color:#2F92EE;'>#血管痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89722, encryptionId=0ce689e223e, topicName=血管痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfab443, createdName=saikp, createdTime=Thu Nov 10 07:38:00 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1741357, encodeId=a1081e41357d9, content=<a href='/topic/show?id=c2c621665c4' target=_blank style='color:#2F92EE;'>#中国专家共识#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21665, encryptionId=c2c621665c4, topicName=中国专家共识)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Jul 30 10:38:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086161, encodeId=f069208616154, content=<a href='/topic/show?id=cee996501dd' target=_blank style='color:#2F92EE;'>#钱菊英#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96501, encryptionId=cee996501dd, topicName=钱菊英)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=bnjfy, createdTime=Mon Jul 11 09:38:00 CST 2016, time=2016-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311740, encodeId=0a8d1311e4079, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1353022, encodeId=71f213530227e, content=<a href='/topic/show?id=1d931321816' target=_blank style='color:#2F92EE;'>#OCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13218, encryptionId=1d931321816, topicName=OCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat May 28 09:38:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87302, encodeId=4a1f8e302c8, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c81702726, createdName=Feng he, createdTime=Fri May 27 10:39:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87295, encodeId=86b38e295cc, content=第一次看到,很有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri May 27 06:59:00 CST 2016, time=2016-05-27, status=1, ipAttribution=)]
    2016-05-27 午夜星河

    第一次看到,很有意思

    0

相关资讯

CIT 2015专访:钱菊英教授:中国冠心病的介入诊疗发展迅速

MedSci专访复旦大学附属中山医院心内科主任医师:钱菊英 MedSci:钱主任,您好!欢迎您来参加2015 CIT介入心脏病学大会。我们都知道您在冠心病的介入诊疗方面造诣颇深,您认为近些年中国冠心病的介入诊疗有什么突破性进展? 钱主任:近些年中国在冠心病的诊疗方面,无论是数量还是质量方面都取得了很大的进展。 首先,从数量方面看,根据霍勇教授统计的数据,201

钱菊英:影像学技术在慢性完全闭塞病变介入治疗中的指导作用

冠状动脉慢性完全闭塞(CTO)病变被认为是目前经皮冠状动脉介入治疗(PCI)领域最大的挑战,近年来不断涌现的新器械和新技术使CTO的手术成功率有了很大的提高,影像学技术的进展在其中发挥了越来越重要的作用。这些影像学技术主要包括:冠脉CT显像(CT-CA)、心脏核磁共振(CMR)、正电子发射计算机断层显像/CT(PET/CT)、血管内超声(IVUS)及光学相干断层显像(OCT)等。前三者为无创性

钱菊英:IVUS和FFR: 指导老年女性患者介入治疗的更佳策略

4月11日上午9点20分,在广州举办的中国南方国际心血管病学术会议的女性心血管病论坛上,来自上海复旦大学附属中山医院的钱菊英教授向我们详细阐述了IVUS和FFR在老年女性患者介入治疗的指导作用。 钱教授首先向我们介绍了女性CHD患者的临床特点。自1980年以来,男性CHD患者的死亡率下降,而女性CHD患者的死亡率反而升高。随着年龄的增加,女性患CHD的风险相对更高。对于心绞痛的病